Substance Abuse Treatment Advisory: Naltrexone

The Center for Substance Abuse Treatment's (CSAT's) latest Substance Abuse Treatment Advisory, Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence (Spring 2007, Volume 6, Issue 1) is available now!

Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence (SMA07-4267)

In April 2006, the U.S. Food and Drug Administration approved a new extended-release injectable formulation of naltrexone (Vivitrol®) for the treatment of alcohol dependence. This issue answers questions treatment providers, particularly counselors and program administrators, may have about injectable naltrexone.

Order your free copy now!

Also available in PDF format

• SAMHSA Office of Applied Studies: Alcohol Use, Binge Drinking, and Alcohol Dependence
• Stop Underage Drinking: Prevention/Treatment Professionals
• Alcohol Policy Information System
• CSAT's Knowledge Application Program (KAP) products

• TIP 28: Naltrexone and Alcoholism Treatment (BKD268)
• TIP 28 Quick Guide for Clinicians (QGCT28)
• TIP 28 KAP Keys for Clinicians (KAPT28)

• The Role of Biomarkers in the Treatment of Alcohol Use Disorders (MS996)
• Acamprosate: A New Medication for Alcohol Use Disorders (MS974)

• Anabolic Steroids (MS991)
• GHB: A Club Drug To Watch (MS915)
• Inhalants (MS922)
• OxyContin®: Prescription Drug Abuse, 2006 Revision (MS726) (PDF)
• Prescription Medications: Misuse, Abuse, Dependence, and Addiction (MS987)

Substance Abuse & Mental Health Services Administration
1 Choke Cherry Road  |  Rockville, MD 20857  |  1-877-SAMHSA-7 (1-877-726-4727)  |  www.samhsa.gov

The Substance Abuse & Mental Health Services Administration (SAMHSA) is the Federal Government's premier source of information about mental health, substance abuse prevention, addictions treatment, and recovery support services.

Please do not reply to this email as this email address is for distribution purposes only.